Comparision of intravitreal dexamethasone implant versus intravitreal bevacizumab along with triamcinolone acetonide injection in diffuse diabetic macular edema

Poster Details

First Author: K.Kumar INDIA

Co Author(s):    S. Latha   A. Agarwal                          

Abstract Details


To compare the efficacy of intravitreal combination therapy with Ozurdex® implant as primary treatment for severe form of diffuse DME (DDME). Intravitreal corticosteroid implant is superior to combination therapy for DDME


The study was done at a tertiary centre in South India


Non-randomized, prospective interventional comparative study. Consecutive patients with DME having CMT>450µ, diffuse leakage on FFA and BCVA between 20/200 to 20/40, received either dexamethasone implant (Group A) or Intravitreal bevacizumab plus triamcinolne acetonide (Group B) injections. Treatment-naive patients were only included for study. Efficacy of the treatment was considered as mean improvement of visual acuity of >2lines (LogMAR of >0.2) and reduction in mean CMT of >250µ


Study included 40 eyes of 34 patients with mean age of 57±6 years. Mean BCVA improved from 0.8 to 0.2 LogMAR and mean OCT reduced from 528 ±184to 245±85µ at 24 weeks (p<0.05). BCVA improved significantly from 0.94 to 0.16 in group A and 0.68 to 0.13 LogMAR units in group B; mean OCT reduced significantly from 591 to 233µ in group A and 465 to 223µ in group B at 24 weeks (p<0.05). Improvement in BCVA and CMT between two groups were comparable at 24 weeks (p=0.26; p=0.31). Retreatment criteria included reduction in BCVA of 2 or more lines and or increase of CMT >150µ at 16 weeks. 5 (26%) eyes in group A and 14 (70%) eyes in group B receieved reinjections. Final CMT following reinjections were comparable between two groups (p=0.12). 2(10%) patients in group A and 8 (40%) patients in group B had transiently increased IOP, controlled medically. No cases of cataract progression attributed to steroid was seen in any of the groups


Intravitreal dexamethasone implant and combined IVB plus TA are equally efficacious as primary treatment for severe diabetic macular edema with anatomical and functional effectiveness at 6 months. Side effects were rare and manageable in our practice. Combination therapy can be offered to patients who cannot afford Ozurdex® implant for severe DDME

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy